Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2019
Filed with the SEC on Jan 8, 2020 and accepted by EDGAR at Jan 8, 2020, 14:39 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-09-01 to 2019-11-30 | $70.0m | us-gaap:Revenues |
| Revenue | 6 months2019-06-01 to 2019-11-30 | $136.0m | us-gaap:Revenues |
| Cost of revenue | 3 months2019-09-01 to 2019-11-30 | $28.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-06-01 to 2019-11-30 | $56.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-09-01 to 2019-11-30 | $41.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2019-06-01 to 2019-11-30 | $79.8m | us-gaap:GrossProfit |
| Research and development | 3 months2019-09-01 to 2019-11-30 | $7.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-06-01 to 2019-11-30 | $14.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-09-01 to 2019-11-30 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-06-01 to 2019-11-30 | −$4.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-09-01 to 2019-11-30 | $41.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-06-01 to 2019-11-30 | $506.0k | us-gaap:InterestExpense |
| Income tax | 3 months2019-09-01 to 2019-11-30 | −$566.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-06-01 to 2019-11-30 | −$682.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-09-01 to 2019-11-30 | −$2.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-06-01 to 2019-11-30 | −$4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-09-01 to 2019-11-30 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-06-01 to 2019-11-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-09-01 to 2019-11-30 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-06-01 to 2019-11-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-09-01 to 2019-11-30 | 37,992,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-06-01 to 2019-11-30 | 37,887,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2019-06-01 to 2019-11-30 | −$597.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-06-01 to 2019-11-30 | $4.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-11-30 | $41.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-11-30 | $132.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-11-30 | $724.9m | us-gaap:Assets |
| Current liabilities | At period end2019-11-30 | $57.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-11-30 | $111.1m | us-gaap:Liabilities |
| Current portion of debt | At period end2019-11-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2019-11-30 | $613.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001275187-20-000005. Last ingested by Listed: Nov 4, 2026, 20:24 ET. Listed shows no prices and gives no investment advice.